R&D for Development of New Drugs for Neglected Diseases How Can India Contribte?

Sudip Chaudhuri ()

Working Papers from eSocialSciences

Abstract: The focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals from 1 January, 2005. WIll this lead increase in resources deveoted to R and D by Indian companies for the development of new drugs more suited to the needs of India and other developing countries? Can the innovation capabilities be utilized for developing new drugs for neglected diseases? Can India contribte to lowering the cost of new drug development and make drugs more accessible?

Keywords: India; resources; TRIPS; pharmaceuticals; developing countries; drugs; diseases; development; developing countries; developed countries; R&D (search for similar items in EconPapers)
Date: 2009-07
New Economics Papers: this item is included in nep-cwa and nep-ino
Note: Institutional Papers
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... &AId=2149&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:2149

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash ().